Sharemaestro company-news research for Ascendis Pharma AS (ASND), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Insufficient evidence
Company news sentiment
ASND news sentiment
Ascendis Pharma AS
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone50Neutral is 50
No current sentiment signal
0/100 evidence confidence
0% direct company focus
0 current stories across 0 publishers
Current company news
The current company-level signal is not yet measurable
Available headlines do not meet the required combination of freshness, direct relevance and independent source depth. The neutral score is a withheld classification, not a neutral forecast.
Available context
+4.7% over one week, -5.6% over four weeks, trend active, and materially above fair value.
Why classification is withheld
No current company-specific story carries enough weight to establish a direct signal.
Evidence confidence is 0/100, below the threshold for a firm classification.
50/100
Weighted toneNo current sentiment signal
0/100
Evidence confidencethin evidence
0%/100
Company focus0 direct stories
N/A/100
Evidence agreementrequires at least 2 stories
News history
Tone and story flow over 21 days
No measurable trajectory yet
The chart will begin when a dated headline passes the relevance and freshness controls.
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth0
0 effective storiesSource breadth0
0 independent publishersDirect relevance0
company-specific evidence shareFreshness0
recency-weighted evidenceAgreement0
requires at least 2 storiesSource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
No sufficiently fresh, directly relevant company news is available for a price comparison.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Insufficient evidence
News subjects
What is shaping the score
Catalyst structure will appear as classified company evidence builds.
Source mix
Where the evidence comes from
No current publisher evidence is available.
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
No qualifying current company evidence
No sufficiently fresh and relevant headline currently passes the evidence rules. Earlier readings remain in the timeline and are not relabelled as a neutral current outlook.
Earlier company news
ASND news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
01
2026
Intellectia AIArchivedPositive tone
ASND News & Events
- Published
- 1 Aug 2026 23:51
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
01
2026
TradingKeyArchivedPositive tone
Ascendis Pharma A/S (ASND) Institutional Confidence
- Published
- 1 Aug 2026 16:28
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
TradingKeyArchivedPositive tone
ASND|Ascendis Pharma A/S|Price:253.204|Chg%:-0.656
- Published
- 28 Jul 2026 15:03
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
Market sourceArchivedPositive tone
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns
- Published
- 25 Jul 2026 20:00
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
24
2026
simplywall.stArchivedPositive tone
Ascendis Pharma (ASND) Could Be 14% Below Fair Value As Growth Hopes Hold
- Published
- 24 Jul 2026 09:17
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
www.timothysykes.comArchivedPositive tone
Ascendis Pharma A/S (ASND) Stock Price | Live Quotes & Charts | NASDAQ
- Published
- 23 Jul 2026 12:10
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
18
2026
Stock Traders DailyArchivedPositive tone
(ASND) Price Dynamics and Execution-Aware Positioning
- Published
- 18 Jul 2026 18:42
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
15
2026
TradingViewArchivedPositive tone
Enterprise value to EBITDA forward of Ascendis Pharma A/S – DUS:A710
- Published
- 15 Jul 2026 12:14
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
15
2026
Investing.comArchivedPositive tone
BofA raises Ascendis Pharma stock price target on revenue outlook
- Published
- 15 Jul 2026 01:34
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
14
2026
Market sourceArchivedPositive tone
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Published
- 14 Jul 2026 06:43
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
13
2026
TradingViewArchivedPositive tone
Price to sales forward of Ascendis Pharma A/S – NASDAQ:ASND
- Published
- 13 Jul 2026 10:34
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
11
2026
MT NewswiresArchivedPositive tone
Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says
- Published
- 11 Jul 2026 03:25
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
08
2026
marketscreener.comArchivedPositive tone
RBC Capital Adjusts Ascendis Pharma Price Target to $280 From $275, Maintains Outperform Rating
- Published
- 8 Jul 2026 12:08
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
06
2026
FinvizArchivedPositive tone
ASND - Ascendis Pharma A/S Volatility & Greeks
- Published
- 6 Jul 2026 10:43
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
Seeking AlphaArchivedPositive tone
Ascendis Pharma: Behind The Stock Surge
- Published
- 3 Jul 2026 16:12
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
Seeking AlphaArchivedPositive tone
Ascendis Pharma Stock: Behind The Stock Surge (NASDAQ:ASND)
- Published
- 3 Jul 2026 01:03
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
01
2026
Investor's Business DailyArchivedPositive tone
Biotech Stocks To Watch And Pharma Industry News
- Published
- 1 Jul 2026 22:35
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
01
2026
Stock TitanArchivedPositive tone
Ascendis Pharma (ASND) shares 2-year TransCon CNP ApproaCH achondroplasia results
- Published
- 1 Jul 2026 14:26
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
30
2026
MT NewswiresArchivedPositive tone
Ascendis Pharma Says Phase 3 Data Show TransCon CNP Improved Leg Alignment in Children With Achondroplasia
- Published
- 30 Jun 2026 18:01
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
30
2026
Stock TitanArchivedPositive tone
Ascendis drug data show leg alignment kept improving through 2 years
- Published
- 30 Jun 2026 14:20
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
30
2026
Stock TitanArchivedPositive tone
Ascendis Pharma (ASND) adds 177,267 shares via warrant exercises
- Published
- 30 Jun 2026 12:27
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
28
2026
MoomooArchivedPositive tone
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap
- Published
- 28 Jun 2026 09:38
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
GuruFocusArchivedPositive tone
Ascendis Pharma (ASND) Joins Multiple Russell Indexes
- Published
- 27 Jun 2026 18:44
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
simplywall.stArchivedPositive tone
Ascendis Pharma (ASND) Could Be 30% Undervalued Following Mixed Share Price Moves
- Published
- 25 Jun 2026 15:45
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
24
2026
富途牛牛ArchivedPositive tone
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating
- Published
- 24 Jun 2026 02:57
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.